Belluscura said it expects products sold in the U.S. will be subject to a tariff production cost hit of up to 20%, and said that its finance chief resigned.

British medical device maker Belluscura said on Wednesday that its products sold in the United States would face tariff of up ...

The order resurrected some policies from Trump’s first administration.

Popular Western medicines for diseases including cancer and diabetes have been caught in the escalating U.S.-China trade war, ...

NEW YORK — The Gellert Global Group, which owns specialty cheese subsidiary Atalanta Corp., has acquired Wisconsin-based ...

Biocon Biologics has reached a settlement with Regeneron, allowing the launch of Yesafili, its biosimilar eye drug, in the US ...

More than 90% of U.S. prescriptions are for generic drugs, yet more than 80% of the raw materials crucial for drug production ...

Operationally-focused buyout group, Ronin Equity Partners in partnership with Landon Capital Partners, announces the sale of ...

The Japan gynecological benign tumor market is witnessing remarkable expansion, with market revenues expected to grow from approximately US$ 1,877.78 million in 2023 to an estimated US$ 4,315.65 ...